Tacrine

As a central neurodegenerative disease, Alzheimer's disease has long been faced with the dilemma of limited clinical intervention means. The advent of tacrine once brought a brand-new treatment path to this field. As the world's first acetylcholinesterase inhibitor approved for Alzheimer's disease, it reversibly inhibits cholinesterase activity, reduces the degradation of acetylcholine, and improves the function of the central cholinergic system, so as to improve the clinical symptoms such as cognitive impairment and memory loss in patients with mild to moderate Alzheimer's disease. Its main applicable population is patients diagnosed with mild to moderate senile dementia, and it is one of the representative drugs in the field of early dementia treatment.

Affected by the continuous rise in the global prevalence of Alzheimer's disease, the market of cholinesterase inhibitor drugs once maintained steady growth. As a first-generation drug, tacrine's peak global annual sales once exceeded 1.2 billion US dollars in the early stage of marketing. However, due to its relatively obvious hepatotoxic adverse reactions, with the subsequent launch of second-generation cholinesterase inhibitors such as donepezil and rivastigmine, the market share of tacrine has declined year by year. At present, it is only used as a clinical alternative drug in some niche markets, and its global market size is less than 50 million US dollars.

The original research enterprise of tacrine is Warner-Lambert Company, and the original research trade name is Cognex. The core compound patent expired in 1998. The main marketed dosage forms are 10mg, 20mg, 30mg and 40mg capsules, and the original research product has been included in the FDA Reference Listed Drug Directory. No tacrine preparation has been approved for marketing in China yet, and there is no registration information of the API of this variety in the database of the Center for Drug Evaluation of the National Medical Products Administration. (Data as of October 2024, please refer to the official website of CDE for the latest information)

CATO can provide a full set of tacrine impurity reference standards, covering various impurity reference substances related to the synthesis process and degradation process. Most products are available in stock. Spot orders placed before 16:00 can be shipped on the same day. All products meet the compliance requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, and can fully meet the use needs of the whole process of API research and development, quality research, registration and declaration, etc.